Clinical Trial Detail

NCT ID NCT03321643
Title Atezolizumab, Gemcitabine, Oxaliplatin, and Rituximab in Treating Patients With Relapsed or Refractory Transformed Diffuse Large B-Cell Lymphoma
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

marginal zone B-cell lymphoma

diffuse large B-cell lymphoma

follicular lymphoma

Therapies

Atezolizumab + Gemcitabine + Oxaliplatin + Rituximab

Atezolizumab + Rituximab

Age Groups: adult senior

No variant requirements are available.